Uncategorized
FDA rejects Sobi’s gout drug over manufacturing issues, sparing Amgen blockbuster
Sobi’s plan to introduce a challenger to Amgen’s blockbuster gout drug Krystexxa has been put on hold by the FDA.
Sobi’s plan to introduce a challenger to Amgen’s blockbuster gout drug Krystexxa has been put on hold by the FDA.